Is tall cell variant papillary thyroid cancer automatically categorized as intermediate risk regardless of other histopathological features and should consequently be treated with RAI?

Tall cell PTC always has a BRAFV600E mutation and should automatically make the patient an ATA intermediate Initial Risk. But not all intermediate risk patients should get RAI RX. With small tumors, no ETE, no nodes AND if the 6 week postop Tg is < 1, I would do "delayed therapy" with "watchful wait...